ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO841

Safety and Tolerability of Tixagevimab/Cilgavimab for Pre-Exposure Prophylaxis of COVID-19 in Kidney Transplant Recipients

Session Information

Category: Transplantation

  • 2002 Transplantation: Clinical

Authors

  • Salinas, Thalia, Weill Cornell Medicine, New York, New York, United States
  • Stryjniak, Gabriel J., Weill Cornell Medicine, New York, New York, United States
  • Lee, John Richard, Weill Cornell Medicine, New York, New York, United States
  • Sawinski, Deirdre L., Weill Cornell Medicine, New York, New York, United States
  • Muthukumar, Thangamani, Weill Cornell Medicine, New York, New York, United States
  • Dadhania, Darshana M., Weill Cornell Medicine, New York, New York, United States
Background

Kidney transplant recipients (KTR) remain at risk for severe COVID-19 because of emerging SARS-CoV-2 variants and impaired antibody response to COVID-19 vaccines. There is an urgent need for effective vaccination and pre-exposure prophylaxis. In December 2021, the FDA issued an emergency use authorization of tixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19 in moderately-severely immunocompromised individuals. In PROVENT, tixagevimab/cilgavimab resulted in 83% relative risk reduction in incidence of symptomatic COVID-19, but only 3% of subjects received immunosuppressive medications and <1% had immunosuppressive disease. We report safety and tolerability of tixagevimab/cilgavimab in KTR at our center.

Methods

40 doses initially allocated to KTR. We designed an online questionnaire to assess therapy tolerability. 28/38 KTR who received therapy responded.

Results

Patient characteristics of 38 KTR who received tixagevimab/cilgavimab are listed (Table 1a). Negative Anti-S antibody documented in 54.1% patients, with 17(85%) testing negative after three vaccines. 28 KTR completed the survey and authorized use of their deidentified data. Most patients, 81.5%, reported tolerating tixagevimab/cilgavimab “Very Well” (Table 1b). The most common symptom was fatigue, moderate in 25% and mild in 29%. Other symptoms were less frequent, <15%.

Conclusion

Tixagevimab/cilgavimab was generally “very well” tolerated. Additional data substantiating safety and tolerability of tixagevimab/cilgavimab over a longer observation period and with more study participants should help increase confidence in a pre-exposure prophylaxis strategy and offer a safety net for kidney transplant recipients and others at risk for severe COVID-19.